The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per 100,000 population respectively in 2015. Moreover, the CDC also estimates the incidence rate of types of IBD across the country. As per the CDC, the incidence of Crohn’s disease and ulcerative colitis were nearly 14.6 and 14.3 per 100,000 population respectively in 2015. Additionally, according to the aforementioned organization, the percentage of people diagnosed with IBD (either Crohn’s disease or ulcerative colitis) increased from 0.9% of US adults in 1999 to 1.3% of US adults in 2015. This percentage is further expected to expand in the near future; thereby, promising significant growth for the IBD market during the forecast period.  

US IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD. 

The companies which are contributing to the growth of the US IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of US IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

Market Segmentation

1. US IBD Market Research and Analysis by Disease Type
2. US IBD Market Research and Analysis by Treatment type

The Report Covers

• Comprehensive research methodology of the US IBD therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US IBD therapeutics market.
• Insights about market determinants which are stimulating the US IBD therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.